Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
67
AORT Quote, Financials, Valuation and Earnings
Last price:
$46.94
Seasonality move
:
-1.32%
Day range:
$46.28 - $48.00
52-week range:
$21.97 - $48.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.95x
P/B ratio:
5.07x
Volume:
387.3K
Avg. volume:
386.3K
1-year change:
64.24%
Market cap:
$2.2B
Revenue:
$388.5M
EPS (TTM):
-$0.24
Analysts' Opinion
-
Consensus RatingArtivion, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $51.71, Artivion, Inc. has an estimated upside of 9.61% from its current price of $46.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $40.00 representing 100% downside risk from its current price of $46.89.
Fair Value
-
According to the consensus of 5 analysts, Artivion, Inc. has 9.61% upside to fair value with a price target of $51.71 per share.
AORT vs. S&P 500
-
Over the past 5 trading days, Artivion, Inc. has overperformed the S&P 500 by 1.32% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Artivion, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Artivion, Inc. has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Artivion, Inc. reported revenues of $113.4M.
Earnings Growth
-
Artivion, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Artivion, Inc. reported earnings per share of $0.13.
Enterprise value:
2.4B
EV / Invested capital:
3.46x
Price / LTM sales:
4.95x
EV / EBIT:
77.13x
EV / Revenue:
5.73x
PEG ratio (5yr expected):
-0.23x
EV / Free cash flow:
153.89x
Price / Operating cash flow:
132.82x
Enterprise value / EBITDA:
44.54x
Gross Profit (TTM):
$258.1M
Return On Assets:
-1.12%
Net Income Margin (TTM):
-2.16%
Return On Equity:
-2.63%
Return On Invested Capital:
-1.36%
Operating Margin:
10.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $339.7M | $384.9M | $422.6M | $95.8M | $113.4M | |
| Gross Profit | $203.5M | $232.5M | $258.1M | $56.9M | $70.9M | |
| Operating Income | $18.3M | $63.5M | $31.4M | $7.8M | $11.6M | |
| EBITDA | $41M | $87.2M | $54.4M | $13.9M | $17.4M | |
| Diluted EPS | -$0.60 | -$0.03 | -$0.24 | -$0.05 | $0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $214.7M | $192.5M | $217.7M | $237.5M | $283.8M | |
| Total Assets | $818.7M | $742.7M | $774.8M | $803.1M | $857.7M | |
| Current Liabilities | $61.1M | $46M | $55M | $152.8M | $85.8M | |
| Total Liabilities | $507.1M | $487.6M | $502.8M | $498.4M | $419M | |
| Total Equity | $311.5M | $255.1M | $272M | $304.7M | $438.7M | |
| Total Debt | $360.3M | $353.1M | $354.1M | $359.3M | $256.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $7.8M | $22.7M | $28.7M | $11.5M | $20.5M | |
| Cash From Investing | -$501K | -$19.4M | -$23M | -$10.6M | -$4.6M | |
| Cash From Financing | $1.6M | $648K | $10.8M | $1.5M | $4.1M | |
| Free Cash Flow | -$401K | $11M | $15.8M | $7.8M | $15.9M | |
AORT
Sector
Market Cap
$2.2B
$28.1M
Price % of 52-Week High
97.29%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
0.5%
-1.49%
1-Year Price Total Return
66.83%
-17.13%
Beta (5-Year)
1.601
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$46.38
200-day SMA
Buy
Level
$35.36
Bollinger Bands (100)
Buy
Level
40.1 - 46.2
Chaikin Money Flow
Buy
Level
22.5M
20-day SMA
Buy
Level
$45.74
Relative Strength Index (RSI14)
Buy
Level
58.04
ADX Line
Buy
Level
14.37
Williams %R
Sell
Level
-19.2101
50-day SMA
Buy
Level
$45.06
MACD (12, 26)
Buy
Level
0.50
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
37.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.1624)
Sell
CA Score
(Annual)
Level (-0.7916)
Buy
Beneish M-Score
(Annual)
Level (-2.5807)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (2.0274)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.
Stock Forecast FAQ
In the current month, AORT has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The AORT average analyst price target in the past 3 months is $51.71.
-
Where Will Artivion, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Artivion, Inc. share price will rise to $51.71 per share over the next 12 months.
-
What Do Analysts Say About Artivion, Inc.?
Analysts are divided on their view about Artivion, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Artivion, Inc. is a Sell and believe this share price will drop from its current level to $40.00.
-
What Is Artivion, Inc.'s Price Target?
The price target for Artivion, Inc. over the next 1-year time period is forecast to be $51.71 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is AORT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Artivion, Inc. is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AORT?
You can purchase shares of Artivion, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Artivion, Inc. shares.
-
What Is The Artivion, Inc. Share Price Today?
Artivion, Inc. was last trading at $46.94 per share. This represents the most recent stock quote for Artivion, Inc.. Yesterday, Artivion, Inc. closed at $46.89 per share.
-
How To Buy Artivion, Inc. Stock Online?
In order to purchase Artivion, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AORT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AORT
Sector
P/E ratio
--
23.89x
PEG ratio
-0.23x
-0.01x
P/B ratio
5.07x
1.81x
Price / LTM sales
4.95x
1.59x
Growth Metrics
AORT
Sector
Revenue growth
18.39%
4.62%
Earnings growth
343.96%
11.06%
Revenue (5-year growth)
7.06%
6.5%
Earnings forecast
$0.15
-$0.21
Profitability
AORT
Sector
Profitability FY 2024
$232.9M
$3.6M
Return on invested capital
-1.36%
-31.84%
Return on assets
-1.12%
-27.96%
Return on equity
-2.63%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
23
Estimated Next Earnings Date
Feb
5
Balance Sheet
AORT
Sector
Total cash
$73.4M
$26.4M
Short term investments
--
$25.7M
Total assets
$789.1M
$76.9M
Long term debt
$256.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
